Active Filter(s):
Details:
Preclinical studies demonstrated that DIOS-202 and DIOS-203 selectively target two distinct epitopes of the SARS-CoV-2 spike protein at once, which largely prevents the emergence of escape mutants.
Lead Product(s): DIOS-202,DIOS-203
Therapeutic Area: Infections and Infectious Diseases Product Name: DIOS-202
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021